Budgetary Healthcare Institution of Omsk Region Regional Clinical Hospital

Recent papers from Budgetary Healthcare Institution of Omsk Region Regional Clinical Hospital

1. Efficacy of comprehensive treatment of patients with acute salpingo-oophoritis and exacerbation of chronic salpingo-oophoritis using a biological medicinal product based on the secretome of peripheral blood leukocytesRussian Journal of Human Reproduction · 2026
2. Clinical and psychopathological models of self-immolation in men: a retrospective analysis of forensic psychiatric examinationsСовременная терапия в психиатрии и неврологии · 2026
3. Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+)Frontiers in Neurology · 2026
4. Analysis of one-year survival and mortality structure of patients with MM according to data from a multicenter Russian prospective studyГематология и трансфузиология · 2026
5. Incidence and Prognostic Value of Bone and Extramedullary Plasmacytomas in Patients with Newly Diagnosed Multiple Myeloma: Data from a Prospective Population-Based StudyClinical oncohematology · 2026
6. Long-term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Final Results of the ADAPT-SC+ Study (P9-9.002)Neurology · 2026
7. Levofloxacin/ketorolac combination versus levofloxacin alone for topically treating moderate-severe acute bacterial conjunctivitis: a randomized controlled trialGraefe s Archive for Clinical and Experimental Ophthalmology · 2026
8. Surgical treatment of an extra-intracanalicular C4 root schwannomaГолова и шея. · 2026
9. Real-World Retention Rate, Effectiveness, and Safety of Netakimab in the Treatment of Patients with Ankylosing Spondylitis: Two-Year Results of the Real Word Evidence LIBRA StudyDoklady Biochemistry and Biophysics · 2026
10. Epidemiological and clinical features of multiple myeloma in Russia: results of a multicenter prospective studyMD-Onco · 2026
11. Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registryS S Korsakov Journal of Neurology and Psychiatry · 2025
12. First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 TrialsJTO Clinical and Research Reports · 2025
13. Tezepelumab in real-world clinical practice: our own experiencePULMONOLOGIYA · 2025
14. Prognosis of pharmacotherapy effectiveness in psoriatic arthritisRheumatology Science and Practice · 2025
15. Orthoflavivirus omskense NS1 Protein Induces Microvascular Endothelial Permeability In VitroViruses · 2025
16. TBEV NS1 Induces Tissue-Specific Microvascular Endothelial Cell Permeability by Activating the TNF-α Signaling PathwayInternational Journal of Molecular Sciences · 2025
17. First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial癌症：英文版 · 2025
18. The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTADoklady Biochemistry and Biophysics · 2025
19. The Efficacy and Safety of Divozilimab in Patient with Systemic Sclerosis: 48-Week Results of the Randomized Double-Blind Placebo-Controlled Phase III Clinical Study LIBERIUSRheumatology Science and Practice · 2025
20. A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertensionEye · 2025